Cessação de análogos da somatostatina após PRRT em tumores neuroendócrinos do intestino médio (STOPNET)
Um estudo randomizado de cessação de análogos da somatostatina após terapia com radionuclídeos do receptor peptídico em tumores neuroendócrinos do intestino médio (STOPNET)
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.
The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.
STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.
The two primary objectives include
-
To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.
-
Feasibility as measured by:
- Recruitment rate and
- Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.
The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: STOPNET Project Manager
- Número de telefone: +61 1300 666 769
- E-mail: gct_stopnet_mailbox@gicancer.org.au
Locais de estudo
-
-
New South Wales
-
Sydney, New South Wales, Austrália, 2065
- Recrutamento
- Royal North Shore Hospital
-
Contato:
- Dr David Chan
- Número de telefone: +61 (02) 8037 4100
- E-mail: david.chan@sydney.edu.au
-
Contato:
- Cindy (Xiaofang) Han
- E-mail: Xiaofang.Han@health.nsw.gov.au
-
Investigador principal:
- Dr David Chan
-
Wollongong, New South Wales, Austrália, 2502
- Recrutamento
- Wollongong Hospital
-
Contato:
- Dr Derrick Siu
- Número de telefone: (02) 4222 5200
- E-mail: howai.siu@health.nsw.gov.au
-
Contato:
- Victoria Cosatto
- Número de telefone: (02) 4222 5738
- E-mail: Victoria.Cosatto@health.nsw.gov.au
-
Investigador principal:
- Dr Derrick Siu
-
-
Queensland
-
Brisbane, Queensland, Austrália, 4006
- Recrutamento
- Royal Brisbane and Womens Hospital
-
Contato:
- Poppy Sharman
- Número de telefone: +61 (07) 3647 0865
- E-mail: Poppy.sharman@health.qld.gov.au
-
Contato:
- A/Prof Matthew Burge
- Número de telefone: +61 07 3636 8111
- E-mail: Matthew.Burge@health.qld.gov.au
-
Investigador principal:
- A/Prof Matthew Burge
-
Cairns, Queensland, Austrália, 4870
- Recrutamento
- Cairns Hospital
-
Contato:
- A/Prof Matthew Burge
- Número de telefone: +61 (07) 4226 0000
- E-mail: Matthew.Burge@health.qld.gov.au
-
Toowoomba, Queensland, Austrália, 4350
- Recrutamento
- Toowoomba Hospital
-
Contato:
- A/Prof Matthew Burge
- Número de telefone: +61 (07) 4616 6000
- E-mail: Matthew.Burge@health.qld.gov.au
-
-
South Australia
-
Adelaide, South Australia, Austrália, 5000
- Recrutamento
- The Queen Elizabeth Hospital
-
Contato:
- Prof Timothy Price
- Número de telefone: 08 8222 6410
- E-mail: Timothy.Price@sa.gov.au
-
Contato:
- Pam Cooper
- Número de telefone: 08 8222 6410
- E-mail: pamela.cooper@sa.gov.au
-
Investigador principal:
- Prof Timothy Price
-
-
Victoria
-
Melbourne, Victoria, Austrália, 3000
- Recrutamento
- Peter MacCallum Cancer Centre
-
Contato:
- Dr Hui-Li Wong
- Número de telefone: +61 3 8559 5000
- E-mail: HuiLi.Wong@petermac.org
-
Investigador principal:
- Dr Hui-Li Wong
-
Contato:
- Naila Pachani
- Número de telefone: +61 3 8559 5000
- E-mail: naila.pachani@petermac.org
-
-
Western Australia
-
Kalgoorlie-Boulder, Western Australia, Austrália, 6430
- Recrutamento
- Kalgoorlie Health Campus
-
Contato:
- Dr Piyush Grover
- Número de telefone: +61 (08) 9080 5888
- E-mail: piyush.grover@health.wa.gov.au
-
Perth, Western Australia, Austrália, 6150
- Recrutamento
- Fiona Stanley Hospital
-
Contato:
- Dr Piyush Grover
- Número de telefone: +61 08 6152 6530
- E-mail: piyush.grover@health.wa.gov.au
-
Contato:
- Anna Cannon
- Número de telefone: +61 08 6152 6719
- E-mail: anna.cannon@health.wa.gov.au
-
Investigador principal:
- Dr Piyush Grover
-
-
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Recrutamento
- Cross Cancer Institute
-
Contato:
- Dr Stella Koumna
- Número de telefone: 780-432-8771
- E-mail: koumna@ualberta.ca
-
Investigador principal:
- Dr Stella Koumna
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- Recrutamento
- BC Cancer Agency, Vancouver Cancer Centre
-
Contato:
- Dr Jon Loree
- Número de telefone: 604-877-6000
- E-mail: jloree@ctg.queensu.ca
-
Contato:
- Tathiana Ruiz
- E-mail: tathiana.ruiz@bccancer.bc.ca
-
Investigador principal:
- Dr Jon Loree
-
-
Ontario
-
London, Ontario, Canadá, N6A 5W9
- Recrutamento
- London Health Sciences Centre Research Institute (LHSCRI)
-
Contato:
- Dr David Laidley
- Número de telefone: 519-685-8500
- E-mail: David.Laidley@lhsc.on.ca
-
Contato:
- Alisha Moynahan
- Número de telefone: 519-685-8500
- E-mail: alisha.moynahan@lhsc.on.ca
-
Investigador principal:
- Dr David Laidley
-
Ottawa, Ontario, Canadá, K1Y 1J8
- Recrutamento
- Ottawa Hospital Research Institute
-
Contato:
- Dr Rachel Goodwin
- Número de telefone: 613-737-8899
- E-mail: rgoodwin@toh.ca
-
Investigador principal:
- Dr Rachel Goodwin
-
Toronto, Ontario, Canadá, M5G 2M9
- Recrutamento
- University Health Network Princess Margaret Cancer Centre
-
Contato:
- Dr Raymond Jang
- Número de telefone: 416-946-6508
- E-mail: raymond.jang@uhn.ca
-
Investigador principal:
- Dr Raymond Jang
-
Toronto, Ontario, Canadá, TG 260
- Recrutamento
- Odette Cancer Centre Sunnybrook Health Sciences Centre
-
Contato:
- Dr Sten Myrehaug
- Número de telefone: 416-480-4834
- E-mail: sten.myrehaug@sunnybrook.ca
-
Investigador principal:
- Dr Sten Myrehaug
-
-
Saskatchewan
-
Regina, Saskatchewan, Canadá, S4T 7T1
- Recrutamento
- Allan Blair Cancer Centre
-
Contato:
- Dr Mussawar Iqbal
- Número de telefone: 306-766-2213
- E-mail: mussawar.iqbal@saskcancer.ca
-
Investigador principal:
- Dr Mussawar Iqbal
-
Saskatoon, Saskatchewan, Canadá, S7N 4H
- Recrutamento
- Saskatoon Cancer Centre
-
Contato:
- Dr Mita Manna
- Número de telefone: 306-655-2640
- E-mail: mita.manna@saskcancer.ca
-
Investigador principal:
- Dr Mita Manna
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).
-
Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.
-
Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).
• Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.
-
Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.
In addition, for this study, non-functioning tumour is defined as:
-
Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.
-
Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.
-
For mid and hind gut (GI cohort) patients:
- 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) <3x upper limit of normal.
- No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
-
Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.
-
-
Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.
-
Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.
-
PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).
-
ECOG performance status 0-2.
-
Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.
-
Adequate renal, hepatic and haematologic function as judged by the treating team.
-
Life expectancy of at least 12 months.
Exclusion Criteria:
- This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
- Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
- Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
- Any contraindication to PRRT, as per local institutional practice.
- Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.
- Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
- Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off corticosteroids for at least 2 weeks.
- Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
- Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
- Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Continue SSA
Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT. |
Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.
Outros nomes:
|
|
Experimental: Cease SSA
Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time. |
Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
20-month progression free survival rate after PRRT
Prazo: 20 months
|
Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA. |
20 months
|
|
Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
Prazo: 20 months
|
|
20 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales
Prazo: 20 months
|
Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning. |
20 months
|
|
Measure Quality of life using the EORTC QLQ-GINET21 scales
Prazo: 20 months
|
Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms. |
20 months
|
|
Cost-effectiveness of SSA therapy cessation
Prazo: The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
|
Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively. |
The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
|
|
Psycho-oncological impacts of SSA therapy cessation: Decision Regret
Prazo: 20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree) |
20 months
|
|
Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression
Prazo: 20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often) |
20 months
|
|
Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict
Prazo: 20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree) |
20 months
|
|
Time to commencement of subsequent therapy
Prazo: 20 months
|
Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies) |
20 months
|
|
Overall survival
Prazo: 20 months
|
Estimate the 20-month overall survival rate in patients who cease and who continue SSA. |
20 months
|
|
Rates of SSA being recommenced over time
Prazo: 20 months
|
Cumulative percentage of SSA recommencement over time. |
20 months
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Exploratory analyses
Prazo: 20 months
|
Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA. |
20 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- AG0219NET
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .